» Articles » PMID: 22471317

Comparison of (64)Cu-complexing Bifunctional Chelators for Radioimmunoconjugation: Labeling Efficiency, Specific Activity, and in Vitro/in Vivo Stability

Overview
Journal Bioconjug Chem
Specialty Biochemistry
Date 2012 Apr 5
PMID 22471317
Citations 64
Authors
Affiliations
Soon will be listed here.
Abstract

High radiolabeling efficiency, preferably to high specific activity, and good stability of the radioimmunoconjugate are essential features for a successful immunoconjugate for imaging or therapy. In this study, the radiolabeling efficiency, in vitro stability, and biodistribution of immunoconjugates with eight different bifunctional chelators labeled with (64)Cu were compared. The anti-CD20 antibody, rituximab, was conjugated to four macrocyclic bifunctional chelators (p-SCN-Bn-DOTA, p-SCN-Bn-Oxo-DO3A, p-SCN-NOTA, and p-SCN-PCTA), three DTPA derivatives (p-SCN-Bn-DTPA, p-SCN-CHX-A″-DTPA, and ITC-2B3M-DTPA), and a macrobicyclic hexamine (sarcophagine) chelator (sar-CO2H) = (1-NH2-8-NHCO(CH2)3CO2H)sar where sar = sarcophagine = 3,6,10,13,16,19-hexaazabicyclo[6.6.6]icosane). Radiolabeling efficiency under various conditions, in vitro stability in serum at 37 °C, and in vivo biodistribution and imaging in normal mice over 48 h were studied. All chelators except sar-CO2H were conjugated to rituximab by thiourea bond formation with an average of 4.9 ± 0.9 chelators per antibody molecule. Sar-CO2H was conjugated to rituximab by amide bond formation with 0.5 chelators per antibody molecule. Efficiencies of (64)Cu radiolabeling were dependent on the concentration of immunoconjugate. Notably, the (64)Cu-NOTA-rituximab conjugate demonstrated the highest radiochemical yield (95%) under very dilute conditions (31 nM NOTA-rituximab conjugate). Similarly, sar-CO-rituximab, containing 1/10th the number of chelators per antibody compared to that of other conjugates, retained high labeling efficiency (98%) at an antibody concentration of 250 nM. In contrast to the radioimmunoconjugates containing DTPA derivatives, which demonstrated poor serum stability, all macrocyclic radioimmunoconjugates were very stable in serum with <6% dissociation of (64)Cu over 48 h. In vivo biodistribution profiles in normal female Balb/C mice were similar for all the macrocyclic radioimmunoconjugates with most of the activity remaining in the blood pool up to 48 h. While all the macrocyclic bifunctional chelators are suitable for molecular imaging using (64)Cu-labeled antibody conjugates, NOTA and sar-CO2H show significant advantages over the others in that they can be radiolabeled rapidly at room temperature, under dilute conditions, resulting in high specific activity.

Citing Articles

Unveiling the potential of copper-61 vs. gallium-68 for SSTR PET imaging.

Fonseca A, Sereno J, Almeida S, Ferreira H, Hrynchak I, Falcao A Eur J Nucl Med Mol Imaging. 2025; .

PMID: 39909885 DOI: 10.1007/s00259-025-07116-2.


Tuning the Properties of Rigidified Acyclic DEDPA Derivatives for Application in PET Using Copper-64.

Torralba-Maldonado D, Marlin A, Lucio-Martinez F, Freire-Garcia A, Whetter J, Brandariz I Inorg Chem. 2024; 63(46):22297-22307.

PMID: 39508185 PMC: 11577316. DOI: 10.1021/acs.inorgchem.4c04050.


Copper-61 is an advantageous alternative to gallium-68 for PET imaging of somatostatin receptor-expressing tumors: a head-to-head comparative preclinical study.

Basaco Bernabeu T, Mansi R, Del Pozzo L, Gaonkar R, McDougall L, Johayem A Front Nucl Med. 2024; 4:1481343.

PMID: 39464654 PMC: 11503464. DOI: 10.3389/fnume.2024.1481343.


Zirconium 89 and Copper 64 for ImmunoPET: From Antibody Bioconjugation and Radiolabeling to Molecular Imaging.

Badier L, Quelven I Pharmaceutics. 2024; 16(7).

PMID: 39065579 PMC: 11279968. DOI: 10.3390/pharmaceutics16070882.


Radiolabeling Diaminosarcophagine with Cyclotron-Produced Cobalt-55 and [Co]Co-NT-Sarcage as a Proof of Concept in a Murine Xenograft Model.

Lin W, Cabrera G, Aluicio-Sarduy E, Barnhart T, Mixdorf J, Li Z Bioconjug Chem. 2024; 35(3):412-418.

PMID: 38411531 PMC: 10954389. DOI: 10.1021/acs.bioconjchem.4c00043.


References
1.
Di Bartolo N, Sargeson A, Smith S . New 64Cu PET imaging agents for personalised medicine and drug development using the hexa-aza cage, SarAr. Org Biomol Chem. 2006; 4(17):3350-7. DOI: 10.1039/b605615f. View

2.
Xiao Z, Donnelly P, Zimmermann M, Wedd A . Transfer of copper between bis(thiosemicarbazone) ligands and intracellular copper-binding proteins. insights into mechanisms of copper uptake and hypoxia selectivity. Inorg Chem. 2008; 47(10):4338-47. DOI: 10.1021/ic702440e. View

3.
Cole W, Denardo S, Meares C, McCall M, Denardo G, Epstein A . Serum stability of 67Cu chelates: comparison with 111In and 57Co. Int J Rad Appl Instrum B. 1986; 13(4):363-8. DOI: 10.1016/0883-2897(86)90011-5. View

4.
Anderson C, Connett J, Schwarz S, Rocque P, Guo L, PHILPOTT G . Copper-64-labeled antibodies for PET imaging. J Nucl Med. 1992; 33(9):1685-91. View

5.
Anderson C, Schwarz S, Connett J, Cutler P, Guo L, Germain C . Preparation, biodistribution and dosimetry of copper-64-labeled anti-colorectal carcinoma monoclonal antibody fragments 1A3-F(ab')2. J Nucl Med. 1995; 36(5):850-8. View